DAPA ACT HF-TIMI 68

DAPA ACT HF-TIMI 68 is an investigator-initiated, randomized, double-blind, placebo-controlled trial in patients with heart failure with reduced ejection fraction (LVEF ≤40%) who have been stabilized during hospitalization for acute heart failure, evaluating the effect of in-hospital initiation of dapagliflozin on the clinical outcome of cardiovascular death or worsening heart failure.

DAPA ACT HF-TIMI 68 trial schema 2020-03-06

DAPA ACT HF on ClinicalTrials.gov

CONTACT US about DAPA ACT HF

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close